BioLineRx (BLRX) Stock Price
BioLineRx Price
Revenue at BioLineRx has contracted by 15.1% per year over the past 16 years to 1.19 M USD. BioLineRx's net margin stands at -99.6%, down from -18.0% several years earlier.
BioLineRx stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioLineRx business model & stock analysis
Frequently asked questions about BioLineRx
Converted at the current exchange rate, the BioLineRx share trades at 1.79 EUR (2.01 USD).
The expected revenue of BioLineRx is 1.62 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioLineRx is -13.66 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioLineRx is currently -0.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioLineRx stock.
The price-to-sales ratio (P/S) of BioLineRx is currently 5.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioLineRx stock.
The Eulerpool Quality Score for BioLineRx is 4/10.
The ISIN of BioLineRx is US09071M3043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of BioLineRx is BLRX. The ticker symbol is used to trade BioLineRx shares on the stock exchange.
BioLineRx stock
BioLineRx Peer Group
All fundamentals and in-depth analysis of BioLineRx
Our stock analysis for BioLineRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLineRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.